Post-Exposure Prophylaxis for HIV Infection: A Clinical Trial Comparing Lopinavir/Ritonavir versus Atazanavir Each with Zidovudine/Lamivudine

Vicens Díaz-Brito(Universitat de Barcelona), Bonaventura Clotet(Universitat de Vic - Universitat Central de Catalunya), Josep M. Gatell(Hospital Clínic de Barcelona), Hernando Knobel(Hospital General de Granollers), Joan Albert Arnáiz(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Agathe León(Hospital Clínic de Barcelona), Peré Domingo(Hospital de Sant Pau), Felipe García(Apple (Israel)), David Dalmau(University Hospital Mútua de Terrassa), Anna Cruceta(Universitat de Barcelona), Joaquim Peraire(Instituto de Salud Carlos III)
Antiviral Therapy
November 25, 2011
10.3851/imp1955
Cited by 32

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
|Science Immunology|2021|638
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile
|AIDS|2001|255